C4 Therapeutics begins Phase 1b trial of cemsidomide with elranatamab

March 25, 2026 7:00 AM

C4 Therapeutics Inc. (NASDAQ: CCCC) announced that the first patient has been dosed in a Phase 1b trial evaluating cemsidomide ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found